RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
ARMD Channel

subscribe to ARMD newsletter
Latest Research : Ophthalmology : Retina : ARMD

   EMAIL   |   PRINT
VISION - VEGF Inhibition Study in Ocular Neovascularization Exploratory Analysis

Oct 8, 2005 - 5:57:00 AM
The study found that early detection and treatment of age-related macular degeneration with pegaptanib sodium may enable AMD patients to maintain and, in some cases, regain vision.

[RxPG] Age-related macular degeneration (AMD) is the leading cause of blindness in older patients in the developed world. Vascular endothelial growth factor is one of the key mediators stimulating the abnormal blood vessel growth and leakage characteristic of the exudative (wet) form of the condition. Pegaptanib sodium (Macugen) is a new treatment for exudative AMD, and has been shown to stabilize vision in approximately 70 percent of cases.

The researchers performed an exploratory analysis of the outcomes of patients with early exudative lesions at week 54 in clinical trials of pegaptanib sodium in the landmark VISION (VEGF Inhibition Study in Ocular Neovascularization) study. The patients were divided into two groups. The researchers found that at week 54, 76 percent of patients in group 1 receiving pegaptanib lost fewer than 15 letters or three lines of vision on the ETDRS eye chart, compared with 50 percent of patients undergoing usual care. In group 2, that proportion was 80 percent and 57 percent, respectively. A number of patients treated with pegaptanib even regained some sight. In addition, patients who underwent usual care for AMD were 10 times more likely to experience severe vision loss than those treated with pegaptanib.

The study found that early detection and treatment of age-related macular degeneration with pegaptanib sodium may enable AMD patients to maintain and, in some cases, regain vision. As a result, the Jules Stein Eye Institute is launching a prospective, open-label, multi-center trial to evaluate the efficacy and safety of pegaptanib in 40 patients with early onset of AMD.

Publication: The research appears in the October 2005 issue of RETINA.
On the web: www.ucla.edu 

Advertise in this space for $10 per month. Contact us today.

Related ARMD News
Deficiency of the Dicer enzyme in retinal cells linked to age-related macular degeneration
Quit smoking to save your eyes
Post Menopausal Hormones - reduces risk of macular degeneration
Higher fish consumption have a reduced risk of advanced age-related macular degeneration
HTRA1 gene linked to aggressive 'wet' age-related macular degeneration
Yellow plant pigments lutein and zeaxanthin reduce risk of age-related macular degeneration
Hormone Therapy Does Not Affect Age-Related Vision Loss
Eating Fish Protects Against Macular Degeneration
Research Highlights Risk Factors For Age-Related Vision Loss
FDA approves ranibizumab for the treatment of wet age-related macular degeneration

Subscribe to ARMD Newsletter

Enter your email address:

 Additional information about the news article
The lead author is Dr. Christine R. Gonzales, assistant professor of ophthalmology at the Jules Stein Eye Institute at UCLA. Eyetech Pharmaceuticals Inc. and Pfizer Inc.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)